July 28, 2020 -- Schrodinger and Viva Biotech have entered a strategic collaboration to expand structure-based drug discovery by generating de novo crystal structures of high-value targets.
Under the terms of the collaboration, Schrodinger will identify drug discovery targets for which there are currently no crystal structures. Viva Biotech will use x-ray crystallography design to structurally enable the targets by generating high-resolution structures with bound ligands.
Schrodinger will then use its computational platform to explore chemical space with the goal of designing novel therapeutic candidates for the targets.